Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects

NCT02383888 PHASE1 COMPLETED Results posted

To investigate the safety, tolerability and pharmacokinetics of BI 425809 tablets in healthy Chinese and Japanese male subjects following the administration of single rising oral doses and further to explore the pharmacokinetics (PK) including dose proportionality of BI 425809 after single dosing of product.

Details

Lead sponsor	Boehringer Ingelheim
Phase	PHASE1
Status	COMPLETED
Enrolment	49
Start date	Mon May 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Healthy

Interventions

• BI 425809
• Placebo

Countries

South Korea